The Group's principal activity is to develop, license, manufacture and market generic pharmaceutical products. It manufactures generic pharmaceutical products like chemical and therapeutically equivalent to a brand name product. These products are marketed to pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, group purchasing organizations, institutions and governmental agencies. On 02-June-2008 it acquired Merck KGaA's CEE generics business.
Alacra Alerts:
Receive alerts on the latest reports on Mylan, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
